Panic disorder affects millions of people worldwide, causing sudden and intense episodes of fear accompanied by physical symptoms such as breathlessness, chest pain and a racing heart.
Standard treatments help many patients, but a substantial proportion either do not respond well or struggle with side effects.
New research suggests that an established antibiotic, used at much lower doses than those prescribed for infections, could offer another option.
A study published in Translational Psychiatry reports that minocycline, a drug commonly used to treat bacterial infections, reduced panic‑like responses in mice and eased panic symptoms in people exposed to a laboratory panic trigger.
The findings raise the possibility that targeting brain inflammation could complement existing treatments.
What is already known about panic disorder
Panic disorder is usually treated with psychological therapies, antidepressants or benzodiazepines such as clonazepam, also known by the brand name Rivotril.
Clonazepam can be effective, but it acts broadly on the brain’s inhibitory GABA system and may cause sedation, slowed breathing, impaired concentration and dependence. Around half of patients do not achieve sufficient symptom control with current medications.
In recent years, researchers have increasingly linked some psychiatric conditions to inflammation in the nervous system, particularly involving microglia, the immune cells of the brain.
Minocycline has long been known to have anti‑inflammatory effects at low doses, separate from its antibiotic action.
What the new study found
The research was carried out by teams at São Paulo State University and the Federal University of Rio de Janeiro, combining animal experiments with a small human study.
In mice, panic‑like behaviour was triggered by brief exposure to high levels of carbon dioxide, which produces a strong sensation of air hunger. Mice that received minocycline for two weeks before exposure showed a reduction in certain panic‑related behaviours, including jumping.
In the human part of the study, 49 people diagnosed with panic disorder inhaled air containing 35 per cent carbon dioxide, a well‑established method for provoking panic symptoms in a controlled setting. Participants were assessed before and after seven days of treatment with either minocycline or clonazepam. Those who took minocycline experienced a reduction in the intensity of panic symptoms, similar to the effect seen with clonazepam.
In simple terms, the study suggests that minocycline can dampen panic responses in both animals and people when panic is experimentally induced.
How it may work
The researchers focused on the locus coeruleus, a small but important brain region involved in arousal, stress responses and sensitivity to carbon dioxide. Using brain tissue from mice, they found that minocycline treatment was associated with a reduction in microglial density in this area several hours after carbon dioxide exposure.
In the human study, blood tests showed that patients taking minocycline had lower levels of pro‑inflammatory cytokines, including interleukin‑6 and tumour necrosis factor alpha, alongside higher levels of interleukin‑10, which has anti‑inflammatory effects.
Together, these findings support the idea that minocycline may reduce panic symptoms by calming inflammation in key brain circuits, rather than by directly altering neurotransmitter signalling as benzodiazepines do.
How strong is the evidence
The results are encouraging but early. The human study was small and short, lasting just one week, and used an experimental panic trigger rather than tracking spontaneous panic attacks in daily life.
The animal findings help explain possible mechanisms but do not guarantee the same effects in people.
Importantly, while changes in inflammatory markers were seen in patients, similar biochemical changes were not clearly detected in the mice, highlighting limits in the methods used and the need for further confirmation.
What this means for patients
This research does not change current medical advice. Minocycline is not approved for treating panic disorder, and people should not take it for this purpose outside clinical supervision. Always talk to your healthcare providers for medical advice.
However, the findings suggest that an anti‑inflammatory approach could be useful, particularly for patients who do not respond to existing psychiatric medicines or cannot tolerate their side effects.
Because minocycline is already widely used and its safety profile is well understood, researchers note that larger clinical trials could move relatively quickly to later phases.
How it fits with current treatments
Clonazepam and similar drugs act on receptors found throughout the brain, which explains both their effectiveness and their side effects. Minocycline appears to act more selectively by reducing inflammation in specific brain regions linked to panic responses.
The doses used in the study were lower than those prescribed for infections, which reduces concerns about antibiotic resistance.
Even so, long‑term use and optimal dosing for psychiatric conditions remain open questions.
What remains unknown
Larger and longer studies are needed to determine whether minocycline can reduce real‑world panic attacks over time, how it compares directly with existing treatments, and which patients are most likely to benefit.
Researchers are also interested in identifying other drugs that act on microglial inflammation and may be even more effective.
The study adds to a growing body of evidence linking inflammation in the brain to mental health conditions.
While much work remains before minocycline could be considered a treatment for panic disorder, the research points towards a broader shift and offers hope in how such conditions may be understood and treated more effectively in the future.
